Plotkin S A, Smiley M L, Friedman H M, Starr S E, Fleisher G R, Wlodaver C, Dafoe D C, Friedman A D, Grossman R A, Barker C F
Lancet. 1984 Mar 10;1(8376):528-30. doi: 10.1016/s0140-6736(84)90930-9.
91 renal transplant candidates were randomised to receive Towne strain cytomegalovirus (CMV) vaccine or placebo at least 8 weeks before transplantation. The vaccine was well tolerated and there was no vaccine virus excretion. Serological and cellular immune responses developed in most vaccines but were lower in the transplant patients than in healthy volunteers and some of the seronegative patients failed to mount responses. CMV infection occurred in most of the seronegative vaccine-treated or placebo-treated patients who received kidneys from seropositive donors, but the illnesses were less severe in the vaccines than those in similarly exposed placebo-treated patients. Vaccine-treated patients who received kidneys from seronegative donors did not excrete virus, and therefore the vaccine virus was not reactivated from a putative latent state despite immunosuppression at the time of transplantation.
91名肾移植候选者在移植前至少8周被随机分组，分别接受汤氏株巨细胞病毒（CMV）疫苗或安慰剂。疫苗耐受性良好，且无疫苗病毒排泄情况。大多数接种疫苗者产生了血清学和细胞免疫反应，但移植患者的反应低于健康志愿者，一些血清学阴性患者未能产生反应。在大多数接受来自血清学阳性供体肾脏的血清学阴性疫苗治疗或安慰剂治疗的患者中发生了CMV感染，但疫苗治疗患者的病情比接受类似暴露安慰剂治疗的患者轻。接受来自血清学阴性供体肾脏的疫苗治疗患者未排泄病毒，因此尽管移植时进行了免疫抑制，但疫苗病毒并未从假定的潜伏状态重新激活。
